Research programme: LDL receptor-transferrin fusion protein - Takeda
Alternative Names: LDL receptor-transferrin fusion protein research programme - Transkaryotic Therapies; LDL receptor-transferrin fusion protein research programme: Takeda; LDL-cholesterol lowering therapies research programme - Transkaryotic Therapies; LDLR/TF; Research programme: LDL-cholesterol lowering therapies - Takeda; TX-1501Latest Information Update: 16 Jan 2019
At a glance
- Originator Shire Pharmaceuticals Group
- Class Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipoproteinaemia type II
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
- 16 Feb 2005 Preclinical trials in Familial hypercholesterolaemia in USA (unspecified route)